市場調査レポート

商品コード

1682712

バイオアベイラビリティ向上技術およびサービス市場：薬剤クラス別、BCS分類タイプ別、バイオアベイラビリティ向上アプローチタイプ別、剤形別、主要地域別：2035年までの業界動向と世界の予測

Bioavailability Enhancement Technologies and Services Market by Type of Drug Class, Type of BCS Classification, Type of Bioavailability Enhancement Approach, Type of Dosage Form, Key Geographical Regions : Industry Trends and Global Forecasts, Till 2035

出版日: 2025年03月19日
発行: Roots Analysis
ページ情報: 英文 270 Pages
納期: 即日から翌営業日

カスタマイズ可能

価格

PDF (Single User License)

USD 4,799 691,343円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (One-Location Site License)

USD 6,999 1,008,275円

レポートPDFを同一所在地における特定事業ユニットに属する全ての方にてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Department License)

USD 10,599 1,526,891円

レポートPDFを部署単位で12名様までご利用いただけるライセンスです。同一部署内であれば、地理的に同じ地点に存在する必要はありません。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise License)

USD 17,999 2,592,935円

レポートPDFを同社の国内外拠点における全ての方にてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=144.06円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界のバイオアベイラビリティ向上技術およびサービスの市場規模は、2035年までの予測期間中に11.11%のCAGRで拡大し、現在の32億米ドルから2035年には102億2,000万米ドルに成長すると予測されています。

近年、薬物の水溶性に関する問題が増加しているため、医薬品開発者の焦点は親油性薬物化合物の開発に移行しています。最近の研究によると、NCEの約90％はBCSクラスIIおよびIVに属しており、これらは低透過性と関連していることが知られています。バイオアベイラビリティが低いために多くの医薬品が市場に出回らないことを考えると、業界ではこの課題を軽減するためのさまざまなツール/方法を模索しています。さらに、多くの企業がバイオアベイラビリティが低い既存の製品候補を再処方しようとしているため、新しいバイオアベイラビリティ向上方法の需要が大幅に高まっています。

2000年以降、バイオアベイラビリティ向上の技術とサービスを提供する55社以上の企業が設立されたことは特筆に値します。競合が激化する中、最先端のツールと技術を利用できることが差別化要因として浮上しました。これにより、多くのサービス/技術プロバイダーが、戦略的な買収/合併、または他のバイオアベイラビリティ向上企業とのサービス提携を通じて、積極的にポートフォリオを拡大しています。医薬品開発者が新しい医薬品ターゲットとクラスの評価を継続するにつれて、バイオアベイラビリティ向上の分野は今後10年間で着実に成長すると予想されます。

アウトソーシングは、薬剤のバイオアベイラビリティを改善するための人気のモデルとして登場しており、約115社がさまざまなバイオアベイラビリティ向上の原則に基づいて幅広いサービスを提供しています。

現在、80%以上の企業が、主に固体分散アプローチを採用して薬物の溶解性を改善することに重点を置いたバイオアベイラビリティ向上サービスを提供しています。バイオアベイラビリティ向上技術の進歩により、薬物動態特性が改善された新しい製剤の開発が可能になり、技術プロバイダーにとって有利な機会が生まれています。技術の50%以上は、小分子、特に経口投与を目的とした分子の生物学的利用能を高めることに重点を置いています。

過去10年間で、さまざまな地理的地域で、バイオアベイラビリティを改善した新しい治療介入を評価するための臨床試験がいくつか登録されました。さまざまなバイオアベイラビリティ向上技術を論じた5,800件以上の論文がさまざまな科学雑誌に掲載されており、この分野における調査活動の急速な進展がうかがえます。バイオアベイラビリティ向上分野は、広範な研究開発活動を特徴としており、複数の高価値技術と強力な知的財産ポートフォリオの開発につながっています。市場が着実に進化する中、新興企業は革新的なバイオアベイラビリティ向上技術を取り入れてサービスポートフォリオを拡充し、競合に勝つ必要があります。

当レポートでは、世界のバイオアベイラビリティ向上技術およびサービス市場について調査し、市場の概要とともに、薬剤クラス別、BCS分類タイプ別、バイオアベイラビリティ向上アプローチタイプ別、剤形別、主要地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

List of Tables

Table 4.1 List of Bioavailability Enhancement Service Providers
Table 4.2 Bioavailability Enhancement Service Providers: Information on Bioavailability Enhancement Principle
Table 4.3 Bioavailability Enhancement Service Providers: Information on Bioavailability Enhancement Approach
Table 4.4 Bioavailability Enhancement Service Providers: Information on Solid Dispersion Approaches
Table 4.5 Bioavailability Enhancement Service Providers: Information on Size Reduction Approaches
Table 4.6 Bioavailability Enhancement Service Providers: Information on Lipid-Based Approaches
Table 4.7 Bioavailability Enhancement Service Providers: Information on Other Bioavailability Enhancement Approaches
Table 4.8 Bioavailability Enhancement Service Providers: Information on Dosage Forms
Table 4.9 Bioavailability Enhancement Service Providers: Information on Routes of Administration
Table 5.1 List of Bioavailability Enhancement Technology Providers
Table 5.2 Bioavailability Enhancement Technologies: Information on Bioavailability Enhancement Principles and Bioavailability Enhancement Approaches
Table 5.3 Bioavailability Enhancement Technologies: Information on Type of Molecule
Table 5.4 Bioavailability Enhancement Technologies: Information on Dosage Forms
Table 5.5 Bioavailability Enhancement Technologies: Information on Routes of Administration
Table 5.6 Bioavailability Enhancement Technologies: Information on Availability for License and Intellectual Property Rights
Table 7.1 Adare Pharma Solutions: Company Snapshot
Table 7.2 Adare Pharma Solutions: Recent Developments and Future Outlook
Table 7.3 Ascendia Pharmaceuticals: Company Snapshot
Table 7.4 Ascendia Pharmaceuticals: Recent Developments and Future Outlook
Table 7.5 Catalent: Company Snapshot
Table 7.6 Catalent: Recent Developments and Future Outlook
Table 7.7 Formulex Pharma Innovations (formerly SoluBest): Company Snapshot
Table 7.8 Formulex Pharma Innovations (formerly SoluBest): Recent Developments and Future Outlook
Table 7.9 Lonza: Company Snapshot
Table 7.10 Lonza: Recent Developments and Future Outlook
Table 7.11 Lubrizol Life Science Health: Company Snapshot
Table 7.12 Lubrizol Life Science Health: Recent Developments and Future Outlook
Table 7.13 Pace Analytical: Company Snapshot
Table 7.14 Pace Analytical: Recent Developments and Future Outlook
Table 7.15 Quotient Sciences: Company Snapshot
Table 7.16 Quotient Sciences: Recent Developments and Future Outlook
Table 7.17 WuXi STA (A Subsidiary of WuXi AppTec): Company Snapshot
Table 7.18 WuXi STA (A Subsidiary of WuXi AppTec): Recent Developments and Future Outlook
Table 9.1 Bioavailability Enhancement: List of Partnerships and Collaborations, since 2013
Table 9.2 Bioavailability Enhancement Focused Partnerships and Collaborations: Information on Type of Agreement (Region-wise and Geography-wise)
Table 11.1 Patent Analysis: Prominent CPC Symbols
Table 11.2 Patent Analysis: Most Popular CPC Symbols
Table 11.3 Patent Analysis: List of Top CPC Symbols
Table 11.4 Patent Analysis: Summary of Benchmarking Analysis
Table 11.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 11.6 Patent Portfolio: List of Leading Patents (in terms of Highest Relative Valuation)
Table 11.7 Patent Portfolio: List of Leading Patents (in terms of Number of Citations)
Table 12.1 Bioavailability Studies: Regulatory Guidelines and Methodologies
Table 15.1 Technologies based on Solid Dispersion Approaches: List of Approved Drugs
Table 15.2 Technologies based on Size Reduction Approaches: List of Approved Drugs
Table 15.3 Technologies based on Lipid-based Approaches: List of Approved Drugs
Table 18.1 Bioavailability Enhancement Service Providers: Distribution by Year of Establishment
Table 18.2 Bioavailability Enhancement Service Providers: Distribution by Company Size
Table 18.3 Bioavailability Enhancement Service Providers: Distribution by Location of Headquarters (Region wise)
Table 18.4 Bioavailability Enhancement Service Providers: Distribution by Location of Headquarters (Country-wise)
Table 18.5 Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Principle
Table 18.6 Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Approach
Table 18.7 Bioavailability Enhancement Service Providers: Distribution by Solid Dispersion Approaches
Table 18.8 Bioavailability Enhancement Service Providers: Distribution by Size Reduction Approaches
Table 18.9 Bioavailability Enhancement Service Providers: Distribution by Lipid-based Approaches
Table 18.10 Bioavailability Enhancement Service Providers: Distribution by Other Bioavailability Enhancement Approaches
Table 18.11 Bioavailability Enhancement Service Providers: Distribution by Dosage Form
Table 18.12 Bioavailability Enhancement Service Providers: Distribution by Route of Administration
Table 18.13 Bioavailability Enhancement Technology Providers: Distribution by Year of Establishment
Table 18.14 Bioavailability Enhancement Technology Providers: Distribution by Company Size
Table 18.15 Bioavailability Enhancement Technology Providers: Distribution by Location of Headquarters (Region-wise)
Table 18.16 Bioavailability Enhancement Technology Providers: Distribution by Location of Headquarters (Country-wise)
Table 18.17 Bioavailability Enhancement Technology Providers: Distribution by Company Size and Location of Headquarters
Table 18.18 Leading Players: Distribution by Number of Technologies
Table 18.19 Bioavailability Enhancement Technologies: Distribution by Bioavailability Enhancement Principle
Table 18.20 Bioavailability Enhancement Technologies: Distribution by Bioavailability Enhancement Approach
Table 18.21 Bioavailability Enhancement Technologies: Distribution by Bioavailability Enhancement Principle and Bioavailability Enhancement Approach
Table 18.22 Bioavailability Enhancement Technologies: Distribution by Type of Molecule
Table 18.23 Bioavailability Enhancement Technologies: Distribution by Bioavailability Enhancement Approach and Type of Molecule
Table 18.24 Bioavailability Enhancement Technologies: Distribution by Dosage Form
Table 18.25 Bioavailability Enhancement Technologies: Distribution by Route of Administration
Table 18.26 Bioavailability Enhancement Technologies: Distribution by Availability for License
Table 18.27 Bioavailability Enhancement Technologies: Distribution by Intellectual Property Rights
Table 18.28 Key Insights: Distribution by Company Size and Location of Headquarters
Table 18.29 Key Insights: Distribution by Location of Headquarters and Bioavailability Enhancement Approach
Table 18.30 Key Insights: Distribution by Bioavailability Enhancement Approach and Dosage Form
Table 18.31 Key Insights: Distribution by Company Size and Bioavailability Enhancement Principle
Table 18.32 Key Insights: Distribution by Bioavailability Enhancement Principle and Bioavailability Enhancement Approach
Table 18.33 Catalent: Annual Revenues, FY 2017 Onwards (USD Billion)
Table 18.34 Lonza: Annual Revenues, FY 2017 Onwards (CHF Billion)
Table 18.35 WuXi STA (A Subsidiary of WuXi AppTec): Annual Revenues, FY 2017 Onwards (USD Billion)
Table 18.36 Partnerships and Collaborations: Cumulative Year-Wise Trend, since 2013
Table 18.37 Partnerships and Collaborations: Distribution by Type of Partnership
Table 18.38 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 18.39 Partnerships and Collaborations: Distribution by Type of Partner
Table 18.40 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 18.41 Most Active Players: Distribution by Number of Partnerships
Table 18.42 Partnerships and Collaborations: Distribution by Location of Headquarters (Region-wise)
Table 18.43 Partnerships and Collaborations: Distribution by Location of Headquarters (Country-wise)
Table 18.44 Partnerships and Collaboration: Distribution by Type of Partnership and Location of Partner Headquarters
Table 18.45 Publication Analysis: Cumulative Distribution by Publication Year, since 2017
Table 18.46 Publication Analysis: Distribution by Type of Publication
Table 18.47 Publication Analysis: Distribution by Bioavailability Enhancement Approach
Table 18.48 Publication Analysis: Distribution by Year of Publication and Bioavailability Enhancement Approach
Table 18.49 Most Popular Journals: Distribution by Number of Publications
Table 18.50 Most Popular Journals: Distribution by Journal Impact Factor
Table 18.51 Most Popular Publishers: Distribution by Number of Publications
Table 18.52 Most Popular Copyright Holders: Distribution by Number of Publications
Table 18.53 Patent Analysis: Distribution by Type of Patent
Table 18.54 Patent Analysis: Cumulative Distribution by Application Year
Table 18.55 Patent Analysis: Cumulative Distribution by Publication Year
Table 18.56 Patent Analysis: Distribution by Year-wise Trend of Filed Patent Applications and Number of Granted Patents
Table 18.57 Patent Analysis: Distribution by Bioavailability Enhancement Approach
Table 18.58 Patent Analysis: Distribution by Publication Year and Bioavailability Enhancement Approach
Table 18.59 Patent Analysis: Distribution by CPC Symbols
Table 18.60 Patent Analysis: Distribution by Location of Patent Jurisdiction (Region-wise)
Table 18.61 Patent Analysis: Distribution by Location of Patent Jurisdiction (Country-wise)
Table 18.62 Patent Analysis: Cumulative Year-wise Distribution by Type of Organization
Table 18.63 Leading Industry Players: Distribution by Number of Patents
Table 18.64 Leading Non-Industry Players: Distribution by Number of Patents
Table 18.65 Leading Patent Assignees: Distribution by Number of Patents
Table 18.66 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Symbols)
Table 18.67 Patent Analysis: Distribution of Patents by Age
Table 18.68 Bioavailability Enhancement: Patent Valuation
Table 18.69 Leading Patents: Distribution by Number of Citations
Table 18.70 Bioavailability Studies: Cumulative Distribution by Trial Registration Year
Table 18.71 Bioavailability Studies: Distribution of Enrolled Patient Population by Trial Registration Year
Table 18.72 Bioavailability Studies: Distribution of Trials by Study Design
Table 18.73 Bioavailability Studies: Distribution of Trials by Trial Phase
Table 18.74 Bioavailability Studies: Distribution of Trials by Recruitment Status
Table 18.75 Bioavailability Studies: Distribution of Trials by Type of Sponsor /Collaborator
Table 18.76 Bioavailability Studies: Distribution of Trials by Type of Molecule and Trial Phase
Table 18.77 Leading Industry Players: Distribution by Number of Registered Trials
Table 18.78 Leading Non-Industry Players: Distribution by Number of Registered Trials
Table 18.79 Bioavailability Studies: Distribution by Study Focus
Table 18.80 Bioavailability Studies: Geographical Distribution of Trials
Table 18.81 Bioavailability Studies: Geographical Distribution of Enrolled Patient Population
Table 18.82 Global Demand for Bioavailability Enhancement Technologies and Services, till 2035 (In Terms of Number of Projects)
Table 18.83 Demand for Bioavailability Enhancement Technologies and Services: Distribution by Drug Class, Current Year and 2035
Table 18.84 Demand for Bioavailability Enhancement Technologies and Services for New Drug Approvals, till 2035 (In Terms of Number of Projects)
Table 18.85 Demand for Bioavailability Enhancement Technologies and Services for Generics, till 2035 (In Terms of Number of Projects)
Table 18.86 Demand for Bioavailability Enhancement Technologies and Services: Distribution by BCS Classification, Current Year and 2035
Table 18.87 Demand for Bioavailability Enhancement Technologies and Services for BCS II Drugs, till 2035 (In Terms of Number of Projects)
Table 18.88 Demand for Bioavailability Enhancement Technologies and Services for BCS IV Drugs, till 2035 (In Terms of Number of Projects)
Table 18.89 Demand for Bioavailability Enhancement Technologies and Services: Distribution by Dosage Form, Current Year and 2035
Table 18.90 Demand for Bioavailability Enhancement Technologies and Services for Liquids, till 2035 (In Terms of Number of Projects)
Table 18.91 Demand for Bioavailability Enhancement Technologies and Services for Solids, till 2035 (In Terms of Number of Projects)
Table 18.92 Demand for Bioavailability Enhancement Technologies and Services for Semi-Solids, till 2035 (In Terms of Number of Projects)
Table 18.93 Demand for Bioavailability Enhancement Technologies and Services for Fine Particles / Powders, till 2035 (In Terms of Number of Projects)
Table 18.94 Demand for Bioavailability Enhancement Technologies and Services for Other Dosage Forms, till 2035 (In Terms of Number of Projects)
Table 18.95 Global Bioavailability Enhancement Services Market, till 2035 (USD Billion)
Table 18.96 Bioavailability Enhancement Services Market: Distribution by Drug Class, Current Year and 2035
Table 18.97 Bioavailability Enhancement Services Market for New Drug Approvals, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 18.98 Bioavailability Enhancement Services Market for Generics, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 18.99 Bioavailability Enhancement Services Market, Current Year and 2035: Distribution by BCS Classification, Current Year and 2035
Table 18.100 Bioavailability Enhancement Services Market for BCS II Drugs, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 18.101 Bioavailability Enhancement Services Market for BCS IV Drugs, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 18.102 Bioavailability Enhancement Services Market, Current Year and 2035: Distribution by Bioavailability Enhancement Approach, Current Year and 2035
Table 18.103 Bioavailability Enhancement Services Market for Lipid Based Approaches, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 18.104 Bioavailability Enhancement Services Market for Size Reduction Based Approaches, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 18.105 Bioavailability Enhancement Services Market for Solid Dispersion Based Approaches, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 18.106 Bioavailability Enhancement Services Market for Other Bioavailability Enhancement Approaches, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 18.107 Bioavailability Enhancement Services Market: Distribution by Dosage Form, Current Year and 2035
Table 18.108 Bioavailability Enhancement Services Market for Liquids, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 18.109 Bioavailability Enhancement Services Market for Solids, till 2035 (USD Billion)
Table 18.110 Bioavailability Enhancement Services Market for Semi-Solids, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 18.111 Bioavailability Enhancement Services Market for Fine Particles / Powders, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 18.112 Bioavailability Enhancement Services Market for Other Dosage Forms, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 18.113 Bioavailability Enhancement Services Market: Distribution by Key Geographies, Current Year and 2035
Table 18.114 Bioavailability Enhancement Services Market in North America, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 18.115 Bioavailability Enhancement Services Market in Europe, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 18.116 Bioavailability Enhancement Services Market in Asia, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 18.117 Bioavailability Enhancement Services Market in Latin America, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 18.118 Bioavailability Enhancement Services Market in Middle East and North Africa, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 18.119 Bioavailability Enhancement Services Market in Rest of the World, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 18.120 Bioavailability Enhancement Services Market: Conservative, Base and Optimistic Scenarios, 2022, 2027 and 2035 (USD Billion)
Table 18.121 Technologies based on Solid Dispersion Approaches: Trends in Intellectual Capital
Table 18.122 Technologies based on Solid Dispersion Approaches: Trends in Research Activity
Table 18.123 Technologies based on Size Reduction Approaches: Trends in Intellectual Capital
Table 18.124 Technologies based on Size Reduction Approaches: Trends in Research Activity
Table 18.125 Technologies based on Lipid-based Approaches: Trends in Intellectual Capital
Table 18.126 Technologies based on Lipid-based Approaches: Trends in Research Activity
Table 18.127 Technology Evaluation Framework: Value Addition Matrix
Table 18.128 Technology Evaluation Matrix

List of Figures

Figure 2.1 Executive Summary: Overall Market Landscape of Bioavailability Enhancement Service Providers
Figure 2.2 Executive Summary: Overall Market Landscape of Bioavailability Enhancement Technologies
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Publication Analysis
Figure 2.5 Executive Summary: Patent Analysis
Figure 2.6 Executive Summary: Clinical Trial Analysis
Figure 2.7 Executive Summary: Demand Analysis
Figure 2.8 Executive Summary: Market Forecast
Figure 3.1 Bioavailability Enhancement Technologies: Historical Evolution of Bioavailability Enhancement Technologies
Figure 3.2 Single Dose Study: Drug Concentration-Time Curve
Figure 3.3 Multiple Dose Study: Drug Concentration-Time Curve
Figure 3.4 Different Bioavailability Assessment Methods
Figure 3.5 Biopharmaceutical Classification System
Figure 3.6 Factors Affecting Drug Bioavailability
Figure 3.7 Solid Dispersion Formulations: Classification
Figure 3.8 Solid Dispersion Formulations: Preparation Methodologies
Figure 3.9 Solid Dispersion Formulations: Melt Agglomeration Technique
Figure 3.10 Nanosuspension Formulations: Preparation Methodologies
Figure 3.11 Lipid-based Formulations: Classification
Figure 3.12 Biological Formulations: Classification
Figure 4.1 Bioavailability Enhancement Service Providers: Distribution by Year of Establishment
Figure 4.2 Bioavailability Enhancement Service Providers: Distribution by Company Size
Figure 4.3 Bioavailability Enhancement Service Providers: Distribution by Location of Headquarters (Region wise)
Figure 4.4 Bioavailability Enhancement Service Providers: Distribution by Location of Headquarters (Country-wise)
Figure 4.5 Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Principle
Figure 4.6 Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Approach
Figure 4.7 Bioavailability Enhancement Service Providers: Distribution by Solid Dispersion Approaches
Figure 4.8 Bioavailability Enhancement Service Providers: Distribution by Size Reduction Approaches
Figure 4.9 Bioavailability Enhancement Service Providers: Distribution by Lipid-based Approaches
Figure 4.10 Bioavailability Enhancement Service Providers: Distribution by Other Bioavailability Enhancement Approaches
Figure 4.11 Bioavailability Enhancement Service Providers: Distribution by Dosage Form
Figure 4.12 Bioavailability Enhancement Service Providers: Distribution by Route of Administration
Figure 5.1 Bioavailability Enhancement Technology Providers: Distribution by Year of Establishment
Figure 5.2 Bioavailability Enhancement Technology Providers: Distribution by Company Size
Figure 5.3 Bioavailability Enhancement Technology Providers: Distribution by Location of Headquarters (Region-wise)
Figure 5.4 Bioavailability Enhancement Technology Providers: Distribution by Location of Headquarters (Country-wise)
Figure 5.5 Bioavailability Enhancement Technology Providers: Distribution by Company Size and Location of Headquarters
Figure 5.6 Leading Players: Distribution by Number of Technologies
Figure 5.7 Bioavailability Enhancement Technologies: Distribution by Bioavailability Enhancement Principle
Figure 5.8 Bioavailability Enhancement Technologies: Distribution by Bioavailability Enhancement Approach
Figure 5.9 Bioavailability Enhancement Technologies: Distribution by Bioavailability Enhancement Principle and Bioavailability Enhancement Approach
Figure 5.10 Bioavailability Enhancement Technologies: Distribution by Type of Molecule
Figure 5.11 Bioavailability Enhancement Technologies: Distribution by Bioavailability Enhancement Approach and Type of Molecule
Figure 5.12 Bioavailability Enhancement Technologies: Distribution by Dosage Form
Figure 5.13 Bioavailability Enhancement Technologies: Distribution by Route of Administration
Figure 5.14 Bioavailability Enhancement Technologies: Distribution by Availability for License
Figure 5.15 Bioavailability Enhancement Technologies: Distribution by Intellectual Property Rights
Figure 6.1 Key Insights: Distribution by Company Size and Location of Headquarters
Figure 6.2 Key Insights: Distribution by Location of Headquarters and Bioavailability Enhancement Approach
Figure 6.3 Key Insights: Distribution by Bioavailability Enhancement Approach and Dosage Form
Figure 6.4 Key Insights: Distribution by Company Size and Bioavailability Enhancement Principle
Figure 6.5 Key Insights: Distribution by Bioavailability Enhancement Principle and Bioavailability Enhancement Approach
Figure 6.6 Key Insights: Distribution by Year of Establishment, Company Size, Number of Bioavailability Enhancement Approaches Offered and Region
Figure 7.1 Adare Pharma Solutions: Bioavailability Enhancement Services Portfolio
Figure 7.2 Ascendia Pharmaceuticals: Bioavailability Enhancement Services Portfolio
Figure 7.3 Catalent: Annual Revenues, FY 2017 Onwards (USD Billion)
Figure 7.4 Catalent: Bioavailability Enhancement Services Portfolio
Figure 7.5 Formulex Pharma Innovations (formerly SoluBest): Bioavailability Enhancement Services Portfolio
Figure 7.6 Lonza: Annual Revenues, FY 2017 Onwards (CHF Billion)
Figure 7.7 Lonza: Bioavailability Enhancement Services Portfolio
Figure 7.8 Lubrizol Life Science Health: Bioavailability Enhancement Services Portfolio
Figure 7.9 Pace Analytical: Bioavailability Enhancement Services Portfolio
Figure 7.10 Quotient Sciences: Bioavailability Enhancement Services Portfolio
Figure 7.11 WuXi STA (A Subsidiary of WuXi AppTec): Annual Revenues, FY 2017 Onwards (USD Billion)
Figure 7.12 WuXi STA (A Subsidiary of WuXi AppTec): Bioavailability Enhancement Services Portfolio
Figure 8.1 Company Benchmarking Analysis: Distribution by Year of Establishment and Location of Headquarters
Figure 8.2 Benchmarking of Players based in North America, Established Pre-2000 (Peer Group I)
Figure 8.3 Benchmarking of Players based in North America, Established 2000-2010 (Peer Group II)
Figure 8.4 Benchmarking of Players based in North America, Established Post-2010 (Peer Group III)
Figure 8.5 Benchmarking of Players based in Europe, Established Pre-2000 (Peer Group IV)
Figure 8.6 Benchmarking of Players based in Europe, Established 2000-2010 (Peer Group V)
Figure 8.7 Benchmarking of Players based in Europe, Established Post-2010 (Peer Group VI)
Figure 8.8 Benchmarking of Players based in Asia and Rest of the World, Established Pre-2000 (Peer Group VII)
Figure 8.9 Benchmarking of Players based in Asia and Rest of the World, Established Post-2000 (Peer Group VIII)
Figure 9.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, since 2013
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 9.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 9.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 9.6 Most Active Players: Distribution by Number of Partnerships
Figure 9.7 Partnerships and Collaborations: Distribution by Location of Headquarters (Region-wise)
Figure 9.8 Partnerships and Collaborations: Distribution by Location of Headquarters (Country-wise)
Figure 9.9 Partnerships and Collaborations: Distribution by Type of Partnership and Location of Partner Headquarters
Figure 10.1 Publication Analysis: Cumulative Distribution by Publication Year, since 2017
Figure 10.2 Publication Analysis: Distribution by Type of Publication
Figure 10.3 Publication Analysis: Distribution by Bioavailability Enhancement Approach
Figure 10.4 Publication Analysis: Distribution by Year of Publication and Bioavailability Enhancement Approach
Figure 10.5 Most Popular Journals: Distribution by Number of Publications
Figure 10.6 Most Popular Journals: Distribution by Journal Impact Factor
Figure 10.7 Most Popular Publishers: Distribution by Number of Publications
Figure 10.8 Most Popular Copyright Holders: Distribution by Number of Publications
Figure 10.9 Publication Analysis: Distribution by Popular Keywords
Figure 11.1 Patent Analysis: Distribution by Type of Patent
Figure 11.2 Patent Analysis: Cumulative Distribution by Application Year
Figure 11.3 Patent Analysis: Cumulative Distribution by Publication Year
Figure 11.4 Patent Analysis: Year-wise Distribution of Filed Patent Applications and Granted Patents
Figure 11.5 Patent Analysis: Distribution by Bioavailability Enhancement Approach
Figure 11.6 Patent Analysis: Distribution by Publication Year and Bioavailability Enhancement Approach
Figure 11.7 Patent Analysis: Distribution by CPC Symbols
Figure 11.8 Patent Analysis: Distribution by Location of Patent Jurisdiction (Region-wise)
Figure 11.9 Patent Analysis: Distribution by Location of Patent Jurisdiction (Country-wise)
Figure 11.10 Patent Analysis: Distribution by Emerging Focus Area
Figure 11.11 Patent Analysis: Cumulative Year-wise Distribution by Type of Organization
Figure 11.12 Leading Industry Players: Distribution by Number of Patents
Figure 11.13 Leading Non-Industry Players: Distribution by Number of Patents
Figure 11.14 Leading Patent Assignees: Distribution by Number of Patents
Figure 11.15 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Symbols)
Figure 11.16 Patent Analysis: Distribution of Patents by Age
Figure 11.17 Bioavailability Enhancement: Patent Valuation
Figure 12.1 Clinical Trial Analysis: Scope and Methodology
Figure 12.2 Bioavailability Studies: Cumulative Distribution by Trial Registration Year
Figure 12.3 Bioavailability Studies: Distribution of Enrolled Patient Population by Trial Registration Year
Figure 12.4 Bioavailability Studies: Distribution of Trials by Study Design
Figure 12.5 Bioavailability Studies: Distribution of Trials by Trial Phase
Figure 12.6 Bioavailability Studies: Distribution of Trials by Recruitment Status
Figure 12.7 Bioavailability Studies: Distribution of Trials by Type of Sponsor / Collaborator
Figure 12.8 Bioavailability Studies: Distribution of Trials by Type of Molecule and Trial Phase
Figure 12.9 Leading Industry Players: Distribution by Number of Registered Trials
Figure 12.10 Leading Non-Industry Players: Distribution by Number of Registered Trials
Figure 12.11 Bioavailability Studies: Distribution by Study Focus
Figure 12.12 Bioavailability Studies: Geographical Distribution of Trials
Figure 12.13 Bioavailability Studies: Geographical Distribution of Enrolled Patient Population
Figure 13.1 Global Demand for Bioavailability Enhancement Technologies and Services, till 2035 (In Terms of Number of Projects)
Figure 13.2 Demand for Bioavailability Enhancement Technologies and Services: Distribution by Drug Class, Current Year and 2035
Figure 13.3 Demand for Bioavailability Enhancement Technologies and Services for New Drug Approvals, till 2035 (In Terms of Number of Projects)
Figure 13.4 Demand for Bioavailability Enhancement Technologies and Services for Generics, till 2035 (In Terms of Number of Projects)
Figure 13.5 Demand for Bioavailability Enhancement Technologies and Services: Distribution by BCS Classification, Current Year and 2035
Figure 13.6 Demand for Bioavailability Enhancement Technologies and Services for BCS II Drugs, till 2035 (In Terms of Number of Projects)
Figure 13.7 Demand for Bioavailability Enhancement Technologies and Services for BCS IV Drugs, till 2035 (In Terms of Number of Projects)
Figure 13.8 Demand for Bioavailability Enhancement Technologies and Services: Distribution by Dosage Form, Current Year and 2035
Figure 13.9 Demand for Bioavailability Enhancement Technologies and Services for Liquids, till 2035 (In Terms of Number of Projects)
Figure 13.10 Demand for Bioavailability Enhancement Technologies and Services for Solids, till 2035 (In Terms of Number of Projects)
Figure 13.11 Demand for Bioavailability Enhancement Technologies and Services for Semi-Solids, till 2035 (In Terms of Number of Projects)
Figure 13.12 Demand for Bioavailability Enhancement Technologies and Services for Fine Particles / Powders, till 2035 (In Terms of Number of Projects)
Figure 13.13 Demand for Bioavailability Enhancement Technologies and Services for Other Dosage Forms, till 2035 (In Terms of Number of Projects)
Figure 14.1 Global Bioavailability Enhancement Services Market, till 2035 (USD Billion)
Figure 14.2 Bioavailability Enhancement Services Market: Distribution by Drug Class, Current Year and 2035
Figure 14.3 Bioavailability Enhancement Services Market for New Drug Approvals, till 2035 (USD Billion)
Figure 14.4 Bioavailability Enhancement Services Market for Generics, till 2035 (USD Billion)
Figure 14.5 Bioavailability Enhancement Services Market, Current Year and 2035: Distribution by BCS Classification, Current Year and 2035
Figure 14.6 Bioavailability Enhancement Services Market for BCS II Drugs, till 2035 (USD Billion)
Figure 14.7 Bioavailability Enhancement Services Market for BCS IV Drugs, till 2035 (USD Billion)
Figure 14.8 Bioavailability Enhancement Services Market, Current Year and 2035: Distribution by Bioavailability Enhancement Approach, Current Year and 2035
Figure 14.9 Bioavailability Enhancement Services Market for Lipid Based Approaches, till 2035 (USD Billion)
Figure 14.10 Bioavailability Enhancement Services Market for Size Reduction Based Approaches, till 2035 (USD Billion)
Figure 14.11 Bioavailability Enhancement Services Market for Solid Dispersion Based Approaches, till 2035 (USD Billion)
Figure 14.12 Bioavailability Enhancement Services Market for Other Bioavailability Enhancement Approaches, till 2035 (USD Billion)
Figure 14.13 Bioavailability Enhancement Services Market: Distribution by Dosage Form, Current Year and 2035
Figure 14.14 Bioavailability Enhancement Services Market for Liquids, till 2035 (USD Billion)
Figure 14.15 Bioavailability Enhancement Services Market for Solids, till 2035 (USD Billion)
Figure 14.16 Bioavailability Enhancement Services Market for Semi-Solids, till 2035 (USD Billion)
Figure 14.17 Bioavailability Enhancement Services Market for Fine Particles / Powders, till 2035 (USD Billion)
Figure 14.18 Bioavailability Enhancement Services Market for Other Dosage Forms, till 2035 (USD Billion)
Figure 14.19 Bioavailability Enhancement Services Market: Distribution by Key Geographies, Current Year and 2035
Figure 14.20 Bioavailability Enhancement Services Market in North America, till 2035 (USD Billion)
Figure 14.21 Bioavailability Enhancement Services Market in Europe, till 2035 (USD Billion)
Figure 14.22 Bioavailability Enhancement Services Market in Asia, till 2035 (USD Billion)
Figure 14.23 Bioavailability Enhancement Services Market in Latin America, till 2035 (USD Billion)
Figure 14.24 Bioavailability Enhancement Services Market in Middle East and North Africa, till 2035 (USD Billion)
Figure 14.25 Bioavailability Enhancement Services Market in Rest of the World, till 2035 (USD Billion)
Figure 14.26 Bioavailability Enhancement Services Market: Conservative, Base and Optimistic Scenarios (USD Billion)
Figure 15.1 Technologies based on Solid Dispersion Approaches: Trends in Intellectual Capital
Figure 15.2 Technologies based on Solid Dispersion Approaches: Trends in Research Activity
Figure 15.3 Technologies based on Size Reduction Approaches: Trends in Intellectual Capital
Figure 15.4 Technologies based on Size Reduction Approaches: Trends in Research Activity
Figure 15.5 Technologies based on Lipid-based Approaches: Trends in Intellectual Capital
Figure 15.6 Technologies based on Lipid-based Approaches: Trends in Research Activity
Figure 15.7 Technology Evaluation Framework: Value Addition Matrix
Figure 15.8 Technology Evaluation Matrix
Figure 16.1 Concluding Remarks: Overall Market Landscape of Bioavailability Enhancement Service Providers
Figure 16.2 Concluding Remarks: Overall Market Landscape of Bioavailability Enhancement Technologies
Figure 16.3 Concluding Remarks: Partnerships and Collaborations
Figure 16.4 Concluding Remarks: Publication Analysis
Figure 16.5 Concluding Remarks: Patent Analysis
Figure 16.6 Concluding Remarks: Clinical Trial Analysis
Figure 16.7 Concluding Remarks: Demand Analysis
Figure 16.8 Concluding Remarks: Market Forecast

Product Code: RA100393

BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES AND SERVICES MARKET: OVERVIEW

As per Roots Analysis, the global bioavailability enhancement technologies and services market is estimated to grow from USD 3.2 billion in the current year to USD 10.22 billion by 2035, at a CAGR of 11.11% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Drug Class

New Drug Approvals
Generics

Type of BCS Classification

BCS II Drugs
BCS IV Drugs

Type of Bioavailability Enhancement Approach

Solid Dispersion
Size Reduction
Lipid-based
Other Approaches

Type of Dosage Form

Liquids
Solids
Semi-Solids
Fine Particles

Key Geographical Regions

North America
Europe
Asia
Latin America
Middle East and North Africa
Rest of the World

BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES AND SERVICES MARKET: GROWTH AND TRENDS

In recent years, the focus of drug developers has shifted towards development of lipophilic drug compounds due to the increasing issues with aqueous solubility of drugs. According to a recent study, around 90% of NCEs belong to BCS class II and IV, which are known to be associated with low permeability. Given that a large number of drugs fail to reach the market due to poor bioavailability, the industry is looking for various tools / methods to mitigate this challenge. Moreover, as many companies seek to re-formulate existing product candidates that exhibit poor bioavailability, the demand for novel bioavailability enhancement methods has grown significantly.

It is worth mentioning that since 2000, more than 55 players offering bioavailability enhancement technologies and services have been established. Amidst the growing competition, the availability of cutting-edge tools and technologies has emerged as a differentiating factor. This has led many service / technology providers to actively expand their portfolios, either through strategic acquisitions / mergers or entering into service alliances with other bioavailability enhancement companies. As drug developers continue to evaluate novel drug targets and classes, the bioavailability enhancement domain is expected to grow at a steady pace over the next decade.

BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES AND SERVICES MARKET: KEY INSIGHTS

The report delves into the current state of the bioavailability enhancement technologies and services market and identifies potential growth opportunities within the industry. Some key findings from the report include:

Outsourcing has emerged as a popular model for improving drug bioavailability, with nearly 115 companies offering a wide range of services based on different bioavailability enhancement principles.

Bioavailability Enhancement Technologies and Services Market - IMG1

At present, more than 80% of the players are offering bioavailability enhancement services focused on improving the drug solubility, primarily by adopting the solid dispersion approach.
Advances in bioavailability enhancement technologies have enabled the development of novel formulations with improved pharmacokinetic properties, resulting in lucrative business opportunities for technology providers.
Over 50% of the technologies are focused on enhancing the bioavailability of small molecules, specifically those intended for delivery via the oral route.
A rise in partnerships focused on bioavailability enhancement services and technology platforms validates the growing interest in this domain; ~40% of such deals were instances of mergers and acquisitions.
In the past decade, several clinical trials have been registered for evaluating novel therapeutic interventions with improved bioavailability, across different geographical regions.
5,800+ articles discussing various bioavailability enhancement techniques have been published in different scientific journals, thereby indicating the rapid pace of research activity within this domain.
Bioavailability enhancement domain is characterized by extensive R&D activity, leading to the development of multiple high value technologies and a strong intellectual property portfolio.
With the market evolving at a steady pace, emerging players need to incorporate innovative bioavailability enhancement technologies to augment their service portfolio and surpass the competition.
Considering the concerns related to low solubility / permeability of certain marketed drugs and a large number of NCEs, the demand for bioavailability enhancement technologies and services is anticipated to rise in the future.
Driven by the increase in number of BCS II and BCS IV molecules being evaluated in early phases of development, the bioavailability enhancement domain is likely to grow at CAGR of ~11%, till 2035.

Bioavailability Enhancement Technologies and Services Market - IMG2

BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES AND SERVICES MARKET: KEY SEGMENTS

New Drug Approvals Occupy the Largest Share of the Bioavailability Enhancement Technologies and Services Market

Based on the type of drug class, the market is segmented into new drug approvals and generics. At present, new drug approvals hold the maximum share of the bioavailability enhancement technologies and services market. This trend is unlikely to change in the near future.

BCS II Drug Class is Likely to Dominate the Bioavailability Enhancement Technologies and Services Market During the Forecast Period

Based on the type of BCS classification, the market is segmented into BCS II drugs and BCS IV drugs. Currently, BCS II drug class holds the maximum share of the bioavailability enhancement technologies and services market. This trend is likely to remain the same in the coming decade.

Size Reduction Approach is the Fastest Growing Segment of the Bioavailability Enhancement Technologies and Services Market During the Forecast Period

Based on the type of bioavailability enhancement approach, the market is segmented into solid dispersion, size reduction, lipid-based and other approaches. It is worth highlighting that, lipid-based approach holds a larger share of the bioavailability enhancement technologies and services market. However, the bioavailability enhancement technologies and services market for size reduction approach is likely to grow at a relatively higher CAGR.

Liquid Dosage Form is Likely to Dominate the Bioavailability Enhancement Technologies and Services Market

Based on the type of dosage form, the market is segmented into liquids, solids, semi-solids and fine particles dosage form. Currently, liquid dosage form holds the maximum share of the bioavailability enhancement technologies and services market. This trend is unlikely to change in the foreseeable future.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia, Middle East and North Africa, Latin America, and Rest of the World. Majority share is expected to be captured by players based in North America. It is worth highlighting that, over the years, the market in Asia is expected to grow at a higher CAGR.

Example Players in the Bioavailability Enhancement Technologies and Services Market

Adare Pharma Solutions
Ascendia Pharmaceuticals
Catalent
Lonza
Lubrizol Life Science Health
Pace Life Sciences
Quotient Sciences
WuXi STA

BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES AND SERVICES MARKET: RESEARCH COVERAGE

Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the bioavailability enhancement technologies and services market, focusing on key market segments, including [A] type of drug class, [B] type of BCS classification, [C] type of bioavailability enhancement approach, [D] type of dosage form, and [J] key geographical regions.
Market Landscape 1: A comprehensive evaluation of bioavailability enhancement service providers, considering various parameters, such as [A] year of establishment, [B] company size (in terms of number of employees), [C] location of headquarters, [D] bioavailability enhancement principle supported, [E] bioavailability enhancement approach employed, [F] type of dosage form supported, and [G] route of administration of drug product.
Market Landscape 2: A comprehensive evaluation of bioavailability enhancement technology providers, considering various parameters, such as [A] year of establishment, [B] company size (in terms of employee count), [C] location of headquarters, [D] bioavailability enhancement principle supported, [E] bioavailability enhancement approach employed, [F] type of molecule, [G] type of dosage form supported, [H] route of administration, [I] availability for license and [J] associated intellectual property rights.
Key Insights: A detailed analysis, encompassing the contemporary market trends, using six schematic representations, including [A] a world map representation depicting the region-wise distribution of various stakeholders engaged in offering bioavailability enhancement services, on the basis of their company size, [B] a waffle chart representation, highlighting the regional distribution of bioavailability enhancement service providers, based on various types of bioavailability enhancement approaches employed by them, [C] a heat map representation of bioavailability enhancement service providers, based on bioavailability enhancement approaches and type of dosage form, [D] a horizontally grouped bar chart, highlighting the distribution of bioavailability enhancement service providers based on their company size and type of bioavailability enhancement principles, [E] an insightful tree map representation of bioavailability enhancement service providers (in terms of bioavailability enhancement principles employed and bioavailability enhancement approaches offered), as well as [F] a 3D bubble analysis comparing the key players engaged in drug bioavailability enhancement market, based on several relevant parameters (such as year of establishment, company size, number of bioavailability enhancement approaches offered and region).
Company Profiles: In-depth profiles of key industry players offering bioavailability enhancement technologies and services, focusing on [A] company overviews, [B] financial information (if available), [C] bioavailability enhancement services portfolio, [D] recent developments and [E] an informed future outlook.
Competitive Benchmarking Analysis: A competitive benchmarking analysis that emphasizes the primary focus areas of various players engaged in the drug bioavailability enhancement market. This analysis compares their existing capabilities within and beyond their respective peer groups based in North America, Europe, Asia-Pacific, and other regions. It offers stakeholders insights into potential strategies for achieving a competitive edge in the industry.
Partnerships and Collaborations: An analysis of partnerships established in this sector, since 2013, covering mergers and acquisitions, licensing agreements, alliances, product development and manufacturing agreements, research and development agreements, product development and commercialization agreements, service agreements, and other agreements.
Publication Analysis: A detailed review of peer-reviewed, scientific articles related to research on bioavailability enhancement of drug compounds and / or drug candidates, based on parameters, such as [A] year of publication, [B] type of publication, [C] popular keywords, [D] top journals, [E] top publishers and [F] top copyright holders (in terms of number of articles published).
Patent Analysis: Detailed analysis of various patents filed / granted related to bioavailability enhancement approaches and technologies based on [A] type of patent, [B] patent application year, [C] patent publication year, [D] bioavailability enhancement approach, [E] CPC symbols, [F] geography, [G] emerging focus area, [H] type of organization, [I] leading industry and non-industry players (in terms of number of patents filed/granted), and [J] individual patent assignees (in terms of size of intellectual property portfolio). It also includes a patent benchmarking analysis and a detailed valuation analysis.
Clinical Trial Analysis: Examination of completed, ongoing, and planned clinical studies of various bioavailability enhancement of various drug compounds and / or candidates based on parameters like [A] trial registration year, [B] trial phase, [C] current recruitment status, [D] enrolled patient population, [E] study design, [F] type of sponsor / collaborator, [G] leading industry and non-industry players (in terms of number of registered trials conducted), [H] type of molecule and [I] key geographies.
Technology Evaluation Framework: An insightful framework evaluating the bioavailability enhancement approaches based on various parameters, such as number of technologies, number of approved drugs, trends highlighted in published literature and patents, and business models adopted by industry stakeholders. It also provides a value addition matrix for respective bioavailability enhancement approaches currently employed by stakeholders.

KEY QUESTIONS ANSWERED IN THIS REPORT

How many companies are currently engaged in this market?
Which are the leading companies in this market?
What kind of partnership models are commonly adopted by industry stakeholders?
What are the factors that are likely to influence the evolution of this market?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

Complimentary PPT Insights Packs
Complimentary Excel Data Packs for all Analytical Modules in the Report
10% Free Content Customization
Detailed Report Walkthrough Session with Research Team
Free Updated report if the report is 6-12 months old or older

1. PREFACE

1.1. Scope of the Report
1.2. Market Segmentation
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. Chapter Overview
3.2. Historical Evolution of Bioavailability Enhancement Technologies
3.3. Assessment of Drug Bioavailability
- 3.3.1. Key Considerations for Bioavailability and Assessment Studies
  - 3.3.1.1. Absolute Bioavailability
  - 3.3.1.2. Relative Bioavailability
  - 3.3.1.3. Single and Multiple Dose Studies
- 3.3.2. Studies in Healthy Subjects and Patients
  - 3.3.2.1. Different Bioavailability Assessment methods
3.4. Need for Bioavailability Enhancement
3.5. Factors Affecting Bioavailability
- 3.5.1. Drug Related Factors
- 3.5.2. Patient Physiology Related Factors
3.6. Bioavailability Enhancement Technologies
- 3.6.1. Physical Technologies for Bioavailability Enhancement
  - 3.6.1.1. Solid Dispersion
    - 3.6.1.1.1. Classification of Solid Dispersion Approaches
    - 3.6.1.1.2. Methodologies for Solid Dispersion Approaches
      - 3.6.1.1.2.1. Hot Melt Extrusion
      - 3.6.1.1.2.2. Melting / Fusion Methods
      - 3.6.1.1.2.3. Solvent Evaporation
      - 3.6.1.1.2.4. Spray-Dried Dispersion
      - 3.6.1.1.2.5. Other Techniques Used for Solid Dispersion
  - 3.6.1.2. Nanosuspension Technology
    - 3.6.1.2.1. Top-Down Approach
    - 3.6.1.2.2. Bottom-Up Approach
- 3.6.2. Chemical Technologies for Bioavailability Enhancement
  - 3.6.2.1. Lipid-Based Formulations
  - 3.6.2.2. Non-Metal-Based Drug Delivery Systems
  - 3.6.2.3. Polymer-Based Drug Delivery Systems
- 3.6.3. Biological Technologies for Bioavailability Enhancement
3.7. Concluding remarks

4. MARKET LANDSCAPE: BIOAVAILABILITY ENHANCEMENT SERVICE PROVIDERS

4.1. Chapter Overview
4.2. Bioavailability Enhancement Service Providers: Overall Market Landscape
- 4.2.1. Analysis by Year of Establishment
- 4.2.2. Analysis by Company Size
- 4.2.3. Analysis by Location of Headquarters
- 4.2.4. Analysis by Bioavailability Enhancement Principle
- 4.2.5. Analysis by Bioavailability Enhancement Approach
  - 4.2.5.1. Analysis by Solid Dispersion Approaches
  - 4.2.5.2. Analysis by Size Reduction Approaches
  - 4.2.5.3. Analysis by Lipid-Based Approaches
  - 4.2.5.4. Analysis by Other Bioavailability Enhancement Approaches
- 4.2.6. Analysis by Dosage Form
- 4.2.7. Analysis by Route of Administration

5. MARKET LANDSCAPE: BIOAVAILABILITY ENHANCEMENT TECHNOLOGY PROVIDERS

5.1. Chapter Overview
5.2. Bioavailability Enhancement Technologies: Technology Providers Landscape
- 5.2.1. Analysis by Year of Establishment
- 5.2.2. Analysis by Company Size
- 5.2.3. Analysis by Location of Headquarters
- 5.2.4. Analysis by Company Size and Location of Headquarters
- 5.2.5. Leading Players: Analysis by Number of Technologies
5.3. Bioavailability Enhancement Technologies: Market Landscape
- 5.3.1. Analysis by Bioavailability Enhancement Principle
- 5.3.2. Analysis by Bioavailability Enhancement Approach
- 5.3.3. Analysis by Bioavailability Enhancement Principle and Bioavailability Enhancement Approach
- 5.3.4. Analysis by Type of Molecule
- 5.3.5. Analysis by Bioavailability Enhancement Approach and Type of Molecule
- 5.3.6. Analysis by Dosage Form
- 5.3.7. Analysis by Route of Administration
- 5.3.8. Analysis by Availability for License
- 5.3.9. Analysis by Intellectual Property Rights

6. KEY INSIGHTS

6.1. Chapter Overview
- 6.1.1. Analysis by Company Size and Location of Headquarters (World Map Representation)
- 6.1.2. Analysis by Location of Headquarters and Bioavailability Enhancement Approach (Waffle Chart)
- 6.1.3. Analysis by Bioavailability Enhancement Approach and Dosage Form (Heatmap Representation)
- 6.1.4. Analysis by Company Size and Bioavailability Enhancement Principle (Horizontally Grouped Bar Chart)
- 6.1.5. Analysis by Bioavailability Enhancement Principle and Bioavailability Enhancement Approach (Tree map Representation)
- 6.1.6. Analysis by Year of Establishment, Company Size, Number of Bioavailability Enhancement Approaches Offered and Region (3D Bubble Chart)

7. COMPANY PROFILES

7.1. Chapter Overview
7.2. Adare Pharma Solutions
- 7.2.1. Company Overview
- 7.2.2. Financial Overview
- 7.2.3. Recent Developments and Future Outlook
7.3. Ascendia Pharmaceuticals
- 7.3.1. Company Overview
- 7.3.2. Financial Overview
- 7.3.3. Recent Developments and Future Outlook
7.4. Catalent
- 7.4.1. Company Overview
- 7.4.2. Financial Overview
- 7.4.3. Recent Developments and Future Outlook
7.5. Formulex Pharma Innovations (formerly SoluBest)
- 7.5.1. Company Overview
- 7.5.2. Financial Overview
- 7.5.3. Recent Developments and Future Outlook
7.6. Lonza
- 7.6.1. Company Overview
- 7.6.2. Financial Overview
- 7.6.3. Recent Developments and Future Outlook
7.7. Lubrizol Life Science Health
- 7.7.1. Company Overview
- 7.7.2. Financial Overview
- 7.7.3. Recent Developments and Future Outlook
7.8. Pace Analytical
- 7.8.1. Company Overview
- 7.8.2. Financial Overview
- 7.8.3. Recent Developments and Future Outlook
7.9. Quotient Sciences
- 7.9.1. Company Overview
- 7.9.2. Financial Overview
- 7.9.3. Recent Developments and Future Outlook
7.10. WuXi STA (A Subsidiary of WuXi AppTec)
- 7.10.1. Company Overview
- 7.10.2. Financial Overview
- 7.10.3. Recent Developments and Future Outlook

8. COMPANY BENCHMARK ANALYSIS

8.1. Chapter Overview
8.2. Company Benchmarking Analysis: Methodology
8.3. Company Benchmarking Analysis: Peer Groups
- 8.3.1. Benchmarking of Players based in North America, Established Pre 2000 (Peer Group I)
- 8.3.2. Benchmarking of Players based in North America, Established 2000-2010 (Peer Group II)
- 8.3.3. Benchmarking of Players based in North America, Established Post 2010 (Peer Group III)
- 8.3.4. Benchmarking of Players based in Europe, Established Pre 2000 (Peer Group IV)
- 8.3.5. Benchmarking of Players based in Europe, Established 2000-2010 (Peer Group V)
- 8.3.6. Benchmarking of Players based in Europe, Established Post 2010 (Peer Group VI)
- 8.3.7. Benchmarking of Players based in Asia and Rest of the World, Established Pre 2000 (Peer Group VII)
- 8.3.8. Benchmarking of Players based in Asia and Rest of the World, Established Post 2000 (Peer Group VIII)

9. PARTNERSHIPS AND COLLABORATIONS

9.1. Chapter Overview
9.2. Partnership Models
9.3. Bioavailability Enhancement: Partnerships and Collaborations
- 9.3.1. Analysis by Year of Partnership
- 9.3.2. Analysis by Type of Partnership
- 9.3.3. Analysis by Year and Type of Partnership
- 9.3.4. Analysis by Type of Partner
- 9.3.5. Analysis by Type of Partnership and Type of Partner
- 9.3.6. Most Active Players: Analysis by Number of Partnerships
9.4. Analysis by Geography
- 9.4.1. Analysis by Region
- 9.4.2. Analysis by Country
- 9.4.3. Analysis by Type of Partnership and Location of Partner Headquarters

10. PUBLICATION ANALYSIS

10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Bioavailability Enhancement: Publication Analysis
- 10.3.1. Analysis by Year of Publication
- 10.3.2. Analysis by Type of Publication
- 10.3.3. Analysis by Bioavailability Enhancement Approach
- 10.3.4. Analysis by Year of Publication and Bioavailability Enhancement Approach
- 10.3.5. Most Popular Journals: Analysis by Number of Publications
- 10.3.6. Most Popular Journals: Analysis of Journal Impact Factor
- 10.3.7. Most Popular Publishers: Analysis by Number of Publications
- 10.3.8. Most Popular Copyright Holders: Analysis by Number of Publications
- 10.3.9. Analysis by Popular Keywords

11. PATENT ANALYSIS

11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Bioavailability Enhancement: Patent Analysis
- 11.3.1. Analysis by Application Year
- 11.3.2. Analysis by Publication Year
- 11.3.3. Analysis by Bioavailability Enhancement Approach
- 11.3.4. Analysis by CPC Symbols
- 11.3.5. Analysis by Geography
- 11.3.6. Analysis by Emerging Focus Areas
- 11.3.7. Analysis by Type of Organization
- 11.3.8. Leading Players: Analysis by Number of Patents
11.4. Bioavailability Enhancement Market: Patent Benchmarking Analysis
- 11.4.1. Analysis by Patent Characteristics
11.5. Bioavailability Enhancement Market: Patent Valuation Analysis
11.6. Leading Patents: Analysis by Number of Citations

12. CLINICAL TRIAL ANALYSIS

12.1. Chapter Overview
12.2. Guidelines To Conduct Bioavailability Studies
12.3. Bioavailability Enhancement: Clinical Trials Analysis
- 12.3.1. Research Methodology
- 12.3.2. Analysis of Trials by Trial Registration Year
- 12.3.3. Analysis of Enrolled Patient Population by Trial Registration Year
- 12.3.4. Analysis of Trials by Study Design
- 12.3.5. Analysis of Trials by Trial Phase
- 12.3.6. Analysis of Trials by Trial Recruitment Status
- 12.3.7. Analysis of Trials by Type of Sponsor / Collaborator
- 12.3.8. Analysis by Type of Molecule and Trial Phase
- 12.3.9. Leading Industry Players: Analysis by Number of Registered Trials
- 12.3.10. Leading Non-Industry Players: Analysis by Number of Registered Trials
- 12.3.11. Analysis by Study Focus
- 12.3.12. Analysis of Trials by Geography
- 12.3.13. Analysis of Enrolled Patient Population by Geography

13. TECHNOLOGY EVALUATION FRAMEWORK

13.1. Chapter Overview
13.2. Key Assumptions and Methodology
13.3. Technologies based on Solid Dispersion Approaches
- 13.3.1. List of Approved Drugs
- 13.3.2. Trends in Intellectual Capital
- 13.3.3. Trends in Research Activity
- 13.3.4. Business Model Adopted by Developers
13.4. Technologies based on Size Reduction Approaches
- 13.4.1. List of Approved Drugs
- 13.4.2. Trends in Intellectual Property
- 13.4.3. Trends in Research Activity
- 13.4.4. Business Model Adopted by Developers
13.5. Technologies based on Lipid-based Approaches
- 13.5.1 List of Approved Drugs
- 13.5.2 Trends in Intellectual Property
- 13.5.3. Trends in Research Activity
- 13.5.4. Business Model Adopted by Developers
13.6. Technology Evaluation Framework: Wind Rose Representation
13.7. Results and Discussions

14. DEMAND ANALYSIS

14.1. Chapter Overview
14.2. Key Assumptions and Methodology
14.3. Global Demand for Bioavailability Enhancement Technologies and Services, till 2035
14.4. Analysis by Drug Class, Current Year and 2035
- 14.4.1. Demand for Bioavailability Enhancement Technologies and Services for New Drug Approvals, till 2035
- 14.4.2. Demand for Bioavailability Enhancement Technologies and Services for Generics, till 2035
14.5. Analysis by BCS Classification, Current Year and 2035
- 14.5.1. Demand for Bioavailability Enhancement Technologies and Services for BCS II Drugs, till 2035
- 14.5.2. Demand for Bioavailability Enhancement Technologies and Services for BCS IV Drugs, till 2035
14.6. Analysis by Dosage Form, Current Year and 2035
- 14.6.1. Demand for Bioavailability Enhancement Technologies and Services for Liquids, till 2035
- 14.6.2. Demand for Bioavailability Enhancement Technologies and Services for Solids, till 2035
- 14.6.3. Demand for Bioavailability Enhancement Technologies and Services for Semi- Solids, till 2035
- 14.6.4. Demand for Bioavailability Enhancement Technologies and Services for Fine Particles / Powders, till 2035
- 14.6.5. Demand for Bioavailability Enhancement Technologies and Services for Other Dosage Forms, till 2035
14.7. Concluding Remarks

15. MARKET FORECAST AND OPPURTUNITY ANALYSIS

15.1. Chapter Overview
15.2. Forecast Methodology and Key Assumptions
15.3. Global Bioavailability Enhancement Services Market, till 2035
15.4. Bioavailability Enhancement Services Market: Analysis by Drug Class, Current

Year and 2035

15.4.1. Bioavailability Enhancement Services Market for New Drug Approvals, till 2035
15.4.2. Bioavailability Enhancement Services Market for Generics, till 2035

15.5. Bioavailability Enhancement Services Market: Analysis by BCS Classification, Current Year and 2035
- 15.5.1. Bioavailability Enhancement Services Market for BCS II Drugs, till 2035
- 15.5.2. Bioavailability Enhancement Services Market for BCS IV Drugs, till 2035
15.6. Bioavailability Enhancement Services Market: Analysis by Bioavailability Enhancement Approach, Current Year and 2035
- 15.6.1. Bioavailability Enhancement Services Market for Lipid Based Approaches, till 2035
- 15.6.2. Bioavailability Enhancement Services Market for Size Reduction Based Approaches, till 2035
- 15.6.3. Bioavailability Enhancement Services Market for Solid Dispersion Based Approaches, till 2035
- 15.6.4. Bioavailability Enhancement Services Market for Other Bioavailability Enhancement Approaches, till 2035
15.7. Bioavailability Enhancement Services Market: Analysis by Dosage Form,

Current Year and 2035

15.7.1. Bioavailability Enhancement Services Market for Liquids, till 2035
15.7.2. Bioavailability Enhancement Services Market for Solids, till 2035
15.7.3. Bioavailability Enhancement Services Market for Semi-Solids, till 2035
15.7.4. Bioavailability Enhancement Services Market for Fine Particles / Powders, till 2035
15.7.5. Bioavailability Enhancement Services Market for Other Dosage Forms, till 2035

15.8. Bioavailability Enhancement Services Market: Analysis by Key Geographies, Current Year and 2035
- 15.8.1. Bioavailability Enhancement Services Market in North America, till 2035
- 15.8.2. Bioavailability Enhancement Services Market in Europe, till 2035
- 15.8.3. Bioavailability Enhancement Services Market in Asia, till 2035
- 15.8.4. Bioavailability Enhancement Services Market in Latin America, till 2035
- 15.8.5. Bioavailability Enhancement Services Market in Middle East and North Africa, till 2035
- 15.8.6. Bioavailability Enhancement Services Market in Rest of the World, till 2035
15.9. Concluding Remarks

バイオアベイラビリティ向上技術およびサービス市場：薬剤クラス別、BCS分類タイプ別、バイオアベイラビリティ向上アプローチタイプ別、剤形別、主要地域別：2035年までの業界動向と世界の予測

Bioavailability Enhancement Technologies and Services Market by Type of Drug Class, Type of BCS Classification, Type of Bioavailability Enhancement Approach, Type of Dosage Form, Key Geographical Regions : Industry Trends and Global Forecasts, Till 2035

目次

第1章 序文

第2章 エグゼクティブサマリー

第3章 イントロダクション

第4章 市場情勢：バイオアベイラビリティ向上サービスプロバイダー

第5章 市場情勢：バイオアベイラビリティ向上技術プロバイダー

第6章 重要な洞察

第7章 企業プロファイル

第8章 企業ベンチマーク分析

第9章 パートナーシップとコラボレーション

第10章 出版物の分析

第11章 特許分析

第12章 臨床試験の分析

第13章 技術評価フレームワーク

第14章 需要分析

第15章 市場予測と機会分析

第16章 結論

第17章 付録I：企業一覧

第18章 付録II：表データ

List of Tables

List of Figures

BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES AND SERVICES MARKET: OVERVIEW

BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES AND SERVICES MARKET: GROWTH AND TRENDS

BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES AND SERVICES MARKET: KEY INSIGHTS

BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES AND SERVICES MARKET: KEY SEGMENTS

Example Players in the Bioavailability Enhancement Technologies and Services Market

BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES AND SERVICES MARKET: RESEARCH COVERAGE

KEY QUESTIONS ANSWERED IN THIS REPORT

REASONS TO BUY THIS REPORT

ADDITIONAL BENEFITS

TABLE OF CONTENTS

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. MARKET LANDSCAPE: BIOAVAILABILITY ENHANCEMENT SERVICE PROVIDERS

5. MARKET LANDSCAPE: BIOAVAILABILITY ENHANCEMENT TECHNOLOGY PROVIDERS

6. KEY INSIGHTS

7. COMPANY PROFILES

8. COMPANY BENCHMARK ANALYSIS

9. PARTNERSHIPS AND COLLABORATIONS

10. PUBLICATION ANALYSIS

11. PATENT ANALYSIS

12. CLINICAL TRIAL ANALYSIS

13. TECHNOLOGY EVALUATION FRAMEWORK

14. DEMAND ANALYSIS

15. MARKET FORECAST AND OPPURTUNITY ANALYSIS

16. CONCLUSION

17. APPENDIX I: LIST OF COMPANIES

18. APPENDIX II: TABULATED DATA

第1章序文

第2章エグゼクティブサマリー

第3章イントロダクション

第4章市場情勢：バイオアベイラビリティ向上サービスプロバイダー

第5章市場情勢：バイオアベイラビリティ向上技術プロバイダー

第6章重要な洞察

第7章企業プロファイル

第8章企業ベンチマーク分析

第9章パートナーシップとコラボレーション

第10章出版物の分析

第11章特許分析

第12章臨床試験の分析

第13章技術評価フレームワーク

第14章需要分析

第15章市場予測と機会分析

第16章結論

第17章付録I：企業一覧

第18章付録II：表データ